STK33 and cancer: However, small‐molecule inhibitors of STK33 identified so far have not shown any effects on cell viability.[24, 42] Recent advancements in the design of targeted degradation of cancer‐promoting proteins, such as proteolysis targeting chimeric (PROTAC) technology, have opened a new avenue for establishing novel anticancer agents.[43] Zhong et al proposed that targeting the degraders of STK33 is a valuable chemical tool for studying the role of STK33 in cancer cells.[25, 26] These findings highlight the potential of targeting STK33 degradation as an anticancer therapeutic strategy.